Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Postpartum. Hypertension
July 12, 2024 updated by: Amera Morad Foad, Sohag University
Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension.
This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping & Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
90
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amera Morad Foad, assistant professor
- Phone Number: +201006591449
- Email: ameramoradfoad@gmail.com
Study Locations
-
-
-
Sohag, Egypt
- Recruiting
- Sohag university hosoital
-
Contact:
- Amera Morad Foad Hamdy, Assistant Professor
- Phone Number: +201006591449
- Email: ameramoradfoad@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Probability Sample
Study Population
Patients who were 18 years or above, and have a diagnosis of postpartum hypertension
Description
Inclusion Criteria:
- Patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to Sohag university hospitals
Exclusion Criteria:
- All pregnant women with medical disorders in pregnancy other than Hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. Also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
denovo postpartum hypertension
females with new onset hypertension after delivary
|
|
persitant postpartum hypertension
females with preexisting hypertension or preeclampsia that persist after delivery
|
|
control
females with normal postpartum blood pressure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Renalase(rs10887800) Genotyping
Time Frame: 1 year
|
The presence of gene polymorphism whether homogenetic or heterogenetic
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Leucocytes telomere length
Time Frame: 1 year
|
Measurement of the relative length of WBCs telomere in patints with postpartum hypertension
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Amera Morad Foad, assistant professor, Sohag University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2024
Primary Completion (Estimated)
June 25, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
July 8, 2024
First Submitted That Met QC Criteria
July 8, 2024
First Posted (Actual)
July 15, 2024
Study Record Updates
Last Update Posted (Actual)
July 16, 2024
Last Update Submitted That Met QC Criteria
July 12, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-24-06-08PD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.